Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.
2.

Atypical antipsychotics for the treatment of disruptive behavior.

Lohr WD, Honaker J.

Pediatr Ann. 2013 Feb;42(2):72-7. doi: 10.3928/00904481-20130128-11. Review. No abstract available.

PMID:
23379410
3.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy JH, Merry SN, Hetrick SE, Stasiak K.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008559. doi: 10.1002/14651858.CD008559.pub2. Review.

PMID:
22972123
4.

Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.

McDougle CJ, Stigler KA, Erickson CA, Posey DJ.

J Clin Psychiatry. 2008;69 Suppl 4:15-20. Review.

5.

The use of atypical antipsychotics in pediatric bipolar disorder.

Chang KD.

J Clin Psychiatry. 2008;69 Suppl 4:4-8. Review.

6.

Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.

McKinney C, Renk K.

Clin Psychol Rev. 2011 Apr;31(3):465-71. doi: 10.1016/j.cpr.2010.11.005. Epub 2010 Nov 18. Review.

PMID:
21130552
8.

Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.

Lorenz RA, Jackson CW, Saitz M.

Pharmacotherapy. 2010 Sep;30(9):942-51. doi: 10.1592/phco.30.9.942. Review.

PMID:
20795849
9.
10.

Role of atypical antipsychotics in the treatment of generalized anxiety disorder.

Hershenberg R, Gros DF, Brawman-Mintzer O.

CNS Drugs. 2014 Jun;28(6):519-33. doi: 10.1007/s40263-014-0162-6. Review.

PMID:
24794100
11.

An update on medication management of behavioral disorders in autism.

Baribeau DA, Anagnostou E.

Curr Psychiatry Rep. 2014 Mar;16(3):437. doi: 10.1007/s11920-014-0437-0. Review.

PMID:
24488702
12.

Atypical antipsychotics in the treatment of children and adolescents: clinical applications.

Findling RL, McNamara NK.

J Clin Psychiatry. 2004;65 Suppl 6:30-44. Review.

13.

The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

Ballard C, Waite J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476. Review.

PMID:
16437455
14.

The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.

Citrome L, Volavka J.

Postgrad Med. 2004 Oct;116(4):49-51, 55-9, 63. Review.

PMID:
15510593
15.

Risperidone in the management of disruptive behavior disorders.

Pandina GJ, Aman MG, Findling RL.

J Child Adolesc Psychopharmacol. 2006 Aug;16(4):379-92. Review.

PMID:
16958564
16.

Second-generation antipsychotics in major depressive disorder: update and clinical perspective.

Chen J, Gao K, Kemp DE.

Curr Opin Psychiatry. 2011 Jan;24(1):10-7. doi: 10.1097/YCO.0b013e3283413505. Review.

PMID:
21088586
17.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
18.

[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].

Erbe S, Gutwinski S, Bschor T.

Psychiatr Prax. 2012 Mar;39(2):57-63. doi: 10.1055/s-0031-1277013. Epub 2011 Dec 21. Review. German.

PMID:
22189902
19.

Metabolic effects of the atypical antipsychotics.

Wooten J.

South Med J. 2007 Aug;100(8):771-2. Review. No abstract available.

PMID:
17713300
20.

Supplemental Content

Support Center